WallStSmart

American Shared Hospital Service (AMS)vsEli Lilly and Company (LLY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 232002% more annual revenue ($65.18B vs $28.08M). LLY leads profitability with a 31.7% profit margin vs -5.5%. LLY earns a higher WallStSmart Score of 78/100 (B+).

AMS

Avoid

29

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 6.7Quality: 5.0

LLY

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 5.0Quality: 6.5
Piotroski: 6/9Altman Z: 2.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMSUndervalued (+73.4%)

Margin of Safety

+73.4%

Fair Value

$8.62

Current Price

$1.34

$7.28 discount

UndervaluedFair: $8.62Overvalued

Intrinsic value data unavailable for LLY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMS1 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$760.43B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
101.2%10/10

Every $100 of equity generates 101 in profit

Profit MarginProfitability
31.7%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
44.9%10/10

Strong operational efficiency at 44.9%

Revenue GrowthGrowth
42.6%10/10

Revenue surging 42.6% year-over-year

EPS GrowthGrowth
51.4%10/10

Earnings expanding 51.4% YoY

Areas to Watch

AMS4 concerns · Avg: 2.3/10
Market CapQuality
$9.57M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-9.4%2/10

ROE of -9.4% — below average capital efficiency

Revenue GrowthGrowth
-14.8%2/10

Revenue declined 14.8%

EPS GrowthGrowth
-38.1%2/10

Earnings declined 38.1%

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
37.0x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.603/10

Elevated debt levels

Price/BookValuation
31.5x2/10

Trading at 31.5x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : AMS

The strongest argument for AMS centers on Price/Book.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.

Bear Case : AMS

The primary concerns for AMS are Market Cap, Return on Equity, Revenue Growth.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.

Key Dynamics to Monitor

AMS profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.

LLY carries more volatility with a beta of 0.50 — expect wider price swings.

LLY is growing revenue faster at 42.6% — sustainability is the question.

LLY generates stronger free cash flow (678M), providing more financial flexibility.

Bottom Line

LLY scores higher overall (78/100 vs 29/100), backed by strong 31.7% margins and 42.6% revenue growth. AMS offers better value entry with a 73.4% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

American Shared Hospital Service

HEALTHCARE · MEDICAL CARE FACILITIES · USA

American Shared Hospital Services rents radiosurgery and radiation therapy equipment to healthcare providers. The company is headquartered in San Francisco, California.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?